Evidence map›Paper›PMID 26119353›Full record

ArticleAlimentary pharmacology & therapeutics2015

Novel association between serum pentraxin-2 levels and advanced fibrosis in well-characterised patients with non-alcoholic fatty liver disease.

E C Verna, J Patel, R Bettencourt, P Nguyen, C Hernandez, M A Valasek, T Kisselva, D A Brenner, R Loomba

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Alimentary pharmacology & therapeutics, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.

  1. Racial and Ethnic Disparities in Nonalcoholic Fatty Liver Disease Prevalence, Severity, and Outcomes in the United States: A Systematic Review and Meta-analysis.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2018
    Pooled it
  2. Article
  3. Article
  4. Article
  5. Pentraxin-3: A Novel Marker for Indicating Liver Fibrosis in Chronic Hepatitis B Patients?The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2021
    Article
  6. Molecular and cellular mechanisms of liver fibrosis and its regression.Nature reviews. Gastroenterology & hepatology · 2021
    Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

E C VernaCenter for Liver Disease and Transplantation, Columbia University College of Physicians and Surgeons, New York, NY, USA.
J PatelInternal Medicine, Department of Medicine, University of California at San Diego, La Jolla, CA, USA.
R BettencourtNAFLD Translational Research Unit, University of California at San Diego, La Jolla, CA, USA.
P NguyenNAFLD Translational Research Unit, University of California at San Diego, La Jolla, CA, USA.
C HernandezNAFLD Translational Research Unit, University of California at San Diego, La Jolla, CA, USA.
M A ValasekDepartment of Pathology, University of California at San Diego, La Jolla, CA, USA.
T KisselvaDivision of Gastroenterology, Department of Medicine, University of California at San Diego, La Jolla, CA, USA.
D A BrennerDivision of Gastroenterology, Department of Medicine, University of California at San Diego, La Jolla, CA, USA.
R LoombaNAFLD Translational Research Unit, University of California at San Diego, La Jolla, CA, USA.
University of California, San Diego · USColumbia University · US

Funding

GENETIC EPIDEMIOLOGY OF NONALCOHOLIC FATTY LIVER DISEASEK23DK090303 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI LOOMBA, ROHIT · 2011 to 2014
$721k
NIDDK NIH HHS K23 DK090303NIDDK NIH HHS K23-DK090303
6 · The paper itself

Abstract

backgroundPentraxin-2 (PTX-2), a serum protein, inhibits inflammation and fibrosis, and recombinant PTX-2 is being tested as an anti-fibrotic agent.

aimTo evaluate the association between serum PTX-2 levels and fibrosis stage in patients with non-alcoholic fatty liver disease (NAFLD).

methodsSerum pentraxin-2 levels were compared between four groups of well-characterised patients including NAFLD with no fibrosis, NAFLD with mild-moderate fibrosis (stage 1-2), NAFLD with advanced fibrosis (stage 3-4), and age-sex matched non-NAFLD controls.

resultsSixty subjects were included in the study. The mean age was 58.9 years, 68% were male and 58% were Caucasian. In univariate analysis, serum PTX-2 levels significantly decreased from non-NAFLD controls to mild NAFLD with no fibrosis, to NAFLD with mild-moderate fibrosis and were lowest in patients with NAFLD and advanced fibrosis, in a dose-dependent manner (P < 0.0001). In multivariable-adjusted analyses controlling for age, sex, albumin, and CRP, the results remained consistent and statistically significant. Serum PTX-2 level had an AUROC of 0.84 (95% CI: 0.71-0.97) for the diagnosis of NAFLD, and an AUROC of 0.77 (95% CI: 0.65-0.90) for the diagnosis of advanced fibrosis in NAFLD. Serum PTX-2 levels also decreased with increasing liver stiffness as estimated by magnetic resonance elastography (r = -0.31, P = 0.02).

conclusionsPTX-2 levels are significantly lower in patients with NAFLD compared to non-NAFLD controls, and decline further in patients with advanced fibrosis. PTX-2 may therefore be both a biomarker of disease and a potential target for anti-fibrotic therapy with the recombinant pentraxin-2.

Indexed as

AdultAgedBiomarkersBlood ProteinsCross-Sectional StudiesFemaleHumansLiver CirrhosisMaleMiddle AgedNon-alcoholic Fatty Liver DiseaseSeverity of Illness IndexBiomarkersBlood Proteins

Identifiers

PMID26119353
PMCPMC7979413
OpenAlexW2163820576

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.